25.10.2019 Heidelberg Pharma AG  DE000A11QVV0

DGAP-News: Heidelberg Pharma AG: Notice to Holders


 

DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous
Heidelberg Pharma AG: Notice to Holders

25.10.2019 / 12:30
The issuer is solely responsible for the content of this announcement.


Notice to Holders

of the convertible bonds issued by Heidelberg Pharma AG (ISIN DE000A2GSZA0 / WKN A11QVV)

Heidelberg Pharma AG ("Issuer") issued convertible bonds in bearer form ("Notes") on 22 November 2017 in the aggregate principal amount of up to EUR 14,968,380.00.

Under Sec. 8.1 of the Terms and Conditions of the Notes, the Issuer is entitled to require the mandatory conversion of the Notes into Issuer shares ("Mandatory Conversion") provided that the Notes have not been redeemed, converted, or repurchased and cancelled as of the maturity date ("Mandatory Conversion Right").

The Issuer hereby gives notice to the holders of the Notes that it is requesting the Mandatory Conversion of the Notes, pursuant to Sec. 8.1 of the Terms and Conditions, on the maturity date (22 November 2019).

Pursuant to Sec. 6.1 of the Terms and Conditions, the Conversion Price for the Mandatory Conversion has been determined to be EUR 2.60. Each Note shall be converted into the number of shares that results by dividing the principal amount of the Note by the Conversion Price.

A total of 14,968,380 Notes with a nominal value of EUR 1.00 each were issued, of which 134,184 Notes had not been converted into shares as of 25 October 2019. With the Mandatory Conversion of the 134,184 outstanding Notes, up to 51,609 new shares will be created, to the extent such Notes have not been converted as of the maturity date (22 November 2019).

The conversion process will be conducted according to Sec. 9 of the Terms and Conditions.

Ladenburg, October 2019

Heidelberg Pharma AG

- The Executive Management Board -

Corresponding press release of 3 November 2017: Heidelberg Pharma AG plans capital measure to fund its ATAC development programs



25.10.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: [email protected]
Internet: www.heidelberg-pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 897381

 
End of News DGAP News Service

897381  25.10.2019 

fncls.ssp?fn=show_t_gif&application_id=897381&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1,90 3,67 7,31 8,49 1,75 18,51 9,86
EBITDA1,2 -10,35 -11,30 -9,60 -17,55 -24,83 -16,62 -20,33
EBITDA-Marge3 -544,74 -307,90 -131,33 -206,71 -1.418,86 -89,79
EBIT1,4 -10,75 -11,67 -10,14 -18,28 -25,63 -17,18 -21,21
EBIT-Marge5 -565,79 -317,98 -138,71 -215,31 -1.464,57 -92,82 -215,11
Jahresüberschuss1 -10,97 -11,67 -10,15 -18,37 -26,14 -19,70 -20,35
Netto-Marge6 -577,37 -317,98 -138,85 -216,37 -1.493,71 -106,43 -206,39
Cashflow1,7 -7,90 -9,98 -8,56 -17,89 -26,61 -8,57 -33,95
Ergebnis je Aktie8 -0,76 -0,41 -0,36 -0,61 -0,80 -0,44 -0,31
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
Heidelberg Pharma
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A11QVV 3,120 Halten 145,41
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -5,58
KBV KCV KUV EV/EBITDA
2,95 - 14,75 -5,29
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 20.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.04.2024 11.07.2024 10.10.2024 25.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,89% -5,40% -16,58% -32,76%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Heidelberg Pharma AG  ISIN: DE000A11QVV0 können Sie bei EQS abrufen


Biotechnologie , A11QVV , HPHA , XETR:WL6